(MRNA) Moderna - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 20.684m USD | Total Return: 151.8% in 12m
Avg Turnover: 303M
Qual. Beats: -1
Rev. Trend: -97.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -120.0 is critical
Extended 1w
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
Moderna, Inc. is a Cambridge-based biotechnology firm specializing in messenger RNA (mRNA) therapeutics and vaccines. Its commercial and developmental portfolio spans respiratory health, latent viruses, oncology, and rare genetic diseases. Key products include Spikevax for COVID-19 and mRESVIA for RSV, with ongoing research into influenza, HIV, and personalized cancer treatments.
The company operates within the high-growth biotechnology sector, where value is primarily driven by intellectual property and clinical trial progression through the FDA pipeline. Moderna utilizes a platform-based business model, allowing it to leverage a single mRNA technology stack across multiple therapeutic areas to potentially accelerate drug development cycles.
Strategic growth is supported by partnerships with major organizations including Merck & Co., Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation. To better understand how these partnerships influence valuation, investors can examine the latest financial metrics on ValueRay.
- Declining COVID-19 vaccine demand impacts core revenue and operational cash flow
- Regulatory approval of RSV and flu vaccines determines near-term growth trajectory
- Clinical trial results for personalized cancer vaccines drive long-term valuation shifts
- Research and development spending levels influence path toward sustained profitability
- Strategic collaborations with Merck and Vertex accelerate pipeline commercialization potential
| Net Income: -3.19b TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 17.98 > 1.0 |
| NWC/Revenue: 151.7% < 20% (prev 164.4%; Δ -12.76% < -1%) |
| CFO/TA -0.13 > 3% & CFO -1.45b > Net Income -3.19b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (395.0m) vs 12m ago 2.33% < -2% |
| Gross Margin: -13.89% > 18% (prev 53.55%; Δ -67.44% > 0.5%) |
| Asset Turnover: 18.39% > 50% (prev 24.71%; Δ -6.31% > 0%) |
| Interest Coverage Ratio: -120.0 > 6 (EBIT TTM -3.12b / Interest Expense TTM 26.0m) |
| A: 0.29 (Total Current Assets 5.77b - Total Current Liabilities 2.40b) / Total Assets 11.5b |
| B: 0.51 (Retained Earnings 5.88b / Total Assets 11.5b) |
| C: -0.26 (EBIT TTM -3.12b / Avg Total Assets 12.1b) |
| D: 1.82 (Book Value of Equity 7.41b / Total Liabilities 4.08b) |
| Altman-Z'' = 3.77 = AA |
| DSRI: 0.68 (Receivables 147.0m/306.0m, Revenue 2.23b/3.14b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.09 (AQ_t 0.25 / AQ_t-1 0.23) |
| SGI: 0.71 (Revenue 2.23b / 3.14b) |
| TATA: -0.15 (NI -3.19b - CFO -1.45b) / TA 11.5b) |
| Beneish M = -3.46 (Cap -4..+1) = AA |
As of June 19, 2026, the stock is trading at USD 63.96 with a total of 21,594,865 shares traded.
Over the past week, the price has changed by +28.85%,
over one month by +32.95%,
over three months by +22.06% and
over the past year by +151.81%.
Moderna has received a consensus analysts rating of 3.22. Therefore, it is recommended to hold MRNA.
- StrongBuy: 5
- Buy: 1
- Hold: 17
- Sell: 3
- StrongSell: 1
| Analysts Target Price | 43.3 | -32.3% |
P/E Forward = 23.0415
P/S = 9.2964
P/B = 2.6733
Revenue TTM = 2.23b USD
EBIT TTM = -3.12b USD
EBITDA TTM = -2.88b USD
Long Term Debt = 590.0m USD (from longTermDebt, last quarter)
Short Term Debt = 50.0m USD (from shortTermDebt, last quarter)
Debt = 2.01b USD (from shortLongTermDebtTotal, last quarter) + Leases 708.0m
Net Debt = -3.20b USD (calculated: Debt 2.01b - CCE 5.21b)
Enterprise Value = 17.5b USD (20.7b + Debt 2.01b - CCE 5.21b)
Interest Coverage Ratio = -120.0 (Ebit TTM -3.12b / Interest Expense TTM 26.0m)
EV/FCF = -11.05x (Enterprise Value 17.5b / FCF TTM -1.58b)
FCF Yield = -9.05% (FCF TTM -1.58b / Enterprise Value 17.5b)
FCF Margin = -71.10% (FCF TTM -1.58b / Revenue TTM 2.23b)
Net Margin = -143.6% (Net Income TTM -3.19b / Revenue TTM 2.23b)
Gross Margin = -13.89% ((Revenue TTM 2.23b - Cost of Revenue TTM 2.53b) / Revenue TTM)
Gross Margin QoQ = -145.5% (prev 33.33%)
Tobins Q-Ratio = 1.52 (Enterprise Value 17.5b / Total Assets 11.5b)
Interest Expense / Debt = 1.30% (Interest Expense 26.0m / Debt 2.01b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -2.46b (EBIT -3.12b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.41 (Total Current Assets 5.77b / Total Current Liabilities 2.40b)
Debt / Equity = 0.27 (Debt 2.01b / totalStockholderEquity, last quarter 7.41b)
Debt / EBITDA = 1.11 (negative EBITDA) (Net Debt -3.20b / EBITDA -2.88b)
Debt / FCF = 2.02 (negative FCF - burning cash) (Net Debt -3.20b / FCF TTM -1.58b)
Total Stockholder Equity = 8.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -26.41% (Net Income -3.19b / Total Assets 11.5b)
RoE = -36.73% (Net Income TTM -3.19b / Total Stockholder Equity 8.70b)
RoCE = -33.60% (EBIT -3.12b / Capital Employed (Equity 8.70b + L.T.Debt 590.0m))
RoIC = -27.29% (negative operating profit) (NOPAT -2.46b / Invested Capital 9.03b)
WACC = 11.11% (E(20.7b)/V(22.7b) * Re(12.09%) + D(2.01b)/V(22.7b) * Rd(1.30%) * (1-Tc(0.21)))
Discount Rate = 12.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 40.45 | Cagr: 0.0%
[DCF] Fair Price = unknown (Cash Flow -1.58b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.77 | # QB: -1
Revenue Correlation: -97.56 | Revenue CAGR: -45.52% | SUE: 0.76 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.09 | Chg30d=+0.11% | Revisions=+14% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-1.13 | Chg30d=+1.48% | Revisions=-43% | Analysts=15
EPS current Year (2026-12-31): EPS=-8.65 | Chg30d=+0.09% | Revisions=-43% | GrowthEPS=-19.1% | GrowthRev=+7.7%
EPS next Year (2027-12-31): EPS=-4.72 | Chg30d=+0.06% | Revisions=+26% | GrowthEPS=+45.4% | GrowthRev=+20.0%
[Analyst] Revisions Ratio: -43%